TABLE 1.
Baseline characteristics of 14 enrolled patients
| Characteristic | Value for characteristic |
|---|---|
| Gendera | |
| Male | 6 (43) |
| Female | 8 (57) |
| Age (years)b | 8.4 (4.3) |
| Racea | |
| White | 2 (14) |
| Black | 9 (64) |
| Asian | 1 (7) |
| Other | 2 (14) |
| Dose of indinavir (mg/m2 q12h)b | 392 (34) |
| Dose of ritonavir (mg/m2 q12h)b | 124 (8) |
| No. (%) of patients having undergone one or more prior antiretroviral therapies (%) | 10 (71) |
| Indinavir q8hc | 8 (80) |
| Indinavir-ritonavir q12hc | 1 (10) |
| Nelfinavirc | 1 (10) |
| Zidovudine + lamivudinec | 10 (100) |
| CD4 cell countb | |
| Cells/mm3 | 824 (613) |
| % of age-specific median cell counts | 75 (44) |
| Plasma HIV RNA viral load (log10 copies/ml)b | 3.60 (1.05) |
| No. of subjects undergoing concomitant treatment | |
| Zidovudine-lamivudine | 12 |
| Didanosine-stavudine | 2 |
| Fluconazole | 1 |
| Terbinafine | 1 |
| Co-trimoxazole | 2 |
a
Number (%) of subjects (total no. of subjects, 14).
b
Mean (standard deviation) for 14 subjects.
c
Number (%) of subjects (total no. of subjects, 10).